<prompt> Answer this question truthfullyWhat is the recommended medical treatment for cellulitis?  <response>: <reason> Appropriate wound care is essential for the management of all diabetic foot ulcers. Uninfected diabetic ulcers do not require antibiotic therapy. For acutely infected wounds, empiric antibiotic with efficacy against Gram-positive cocci should be initiated after obtaining a post- debridement specimen for aerobic and anaerobic culture. Infections with antibiotic-resistant organisms and those that are chronic, previously treated, or severe usually require broader spectrum regimens. Click on the following categories to expand treatment regimens.Uninfected Grade 1 No Evidence of Infection Mild Grade 2 Acute Infection Without Recent Antibiotic Use High Risk for MRSA Moderate to Severe Grade 34 Chronic Infection or Recent Antibiotic Use High Risk for MRSA High Risk for Pseudomonas aureuginosa Polymicrobial Infection Uninfected Wound, No Evidence of Infection Uninfected wounds should be managed with appropriate wound care. Antibiotic therapy is not recommended. Mild DFI, Acute Infection Without Recent Antibiotic Use Preferred Regimen Dicloxacillin 125250 mg PO qid OR Clindamycin 150300 mg PO qid OR Cephalexin 500 mg PO qid OR Levofloxacin 750 mg PO qd OR Amoxicillin-Clavulanate 500 mg PO bid or 250 mg PO tid Usually active against community-associated MRSA, but check macrolide sensitivity and consider ordering a D-test before using for MRSA. Relatively broad-spectrum oral agent that includes anaerobic coverage. Mild DFI, High Risk for MRSA Preferred Regimen Doxycycline 100 mg PO q12h OR TMPSMX 80-160 mg400-800 mg PO q12h Active against many MRSA some gram-negatives; uncertain against streptococci. Moderate to Severe DFI, Chronic Infection or Recent Antibiotic Use Preferred Regimen Levofloxacin 750 mg IVPO q24h OR Cefoxitin 1 g IV q4h or 2 g IV q68h OR Ceftriaxone 12 gday IVIM q1224h OR AmpicillinSulbactam 1.53 g IVIM q6h OR Moxifloxacin 400 mg IVPO q24h OR Ertapenem 1 g IVIM q24h OR Tigecycline 100 mg IV, then 50 mg IV q12h OR ImipenemCilastatin 0.51 g IV q68h Alternative Regimen Levofloxacin 750 mg IVPO q24h OR Ciprofloxacin 6001200 mgday IV q612h OR Ciprofloxacin 12002700 mg IV q612h for more severe cases PLUS Clindamycin 150300 mg PO qid Active against MRSA. Not active against MRSA; consider when ESBL-producing pathogens suspected. Moderate to Severe DFI, High Risk for MRSA Preferred Regimen Linezolid 600 mg IVPO q12h OR Daptomycin 4 mgkg IV q24h OR Vancomycin 1520 mgkg IV q812h trough: 1020 mgL Moderate to Severe DFI, High Risk for Pseudomonas aeruginosa Preferred Regimen PiperacillinTazobactam 3.375 g IV q68h Moderate to Severe DFI, Polymicrobial Infection Preferred Regimen Vancomycin 1520 mgkg IV q812h trough: 1020 mgL OR Linezolid 600 mg IVPO q12h OR Daptomycin 4 mgkg IV q24h PLUS PiperacillinTazobactam 3.375 g IV q68h OR ImipenemCilastatin 0.51 g IV q68h OR Ertapenem 1 g IVIM q24h OR Meropenem 1 g IV q8h Alternative Regimen Vancomycin 1520 mgkg IV q812h trough: 1020 mgL OR Linezolid 600 mg IVPO q12h OR Daptomycin 4 mgkg IV q24h PLUS Ceftazidime 2 g IV q8h OR Cefepime 2 g IV q8h OR Aztreonam 2 g IV q68h PLUS Metronidazole 15 mgkg IV, then 7.5 mgkg IV q6h 